Dermatitis News

Rinvoq showed long-term efficacy and safety up to 140 weeks in the treatment of moderate to severe atopic dermatitis in adults and adolescents aged 12 years and older, AbbVie announced in a press release.

Opzelura achieved significant efficacy for the treatment of atopic dermatitis in children aged as young as 2 years, Incyte announced in a press release.

Eczema, a chronic skin disease, affects about 31.6 million Americans with potentially debilitating physical pain and discomfort, as well as putting a significant damper on their social and emotional well-being.

Amlitelimab exhibited clinically meaningful efficacy over 24 weeks in the treatment of adults with moderate to severe atopic dermatitis, according to study results presented at the European Academy of Dermatology and Venereology 2023 Congress.

With dozens of topical therapies and systemic treatments available for atopic dermatitis, clinicians have many options. But a pair of reviews in The Journal of Allergy and Clinical Immunology may help them narrow down their choices.

Dermavant Sciences has announced new “highly favorable” phase 3 pruritus data for Vtama cream for the treatment of moderate to severe atopic dermatitis in adults and children aged as young as 2 years, according to a press release.

Each year, WHO marks World Mental Health Day on Oct. 10 in an effort to raise awareness of mental health issues around the world and mobilize efforts to support mental health.

Children with vs. without atopic dermatitis are more likely to have positive patch-test reactions for allergic contact dermatitis, according to a study.

NEW YORK — Speakers at the Skin of Color Update 2023 meeting discussed the additional diagnostic criteria that are necessary to consider in order to properly diagnose eczema in patients with skin of color.

Patients in sexual and gender minorities who have chronic inflammatory skin diseases often experience financial and non-financial barriers to care, according to a study.